What is the current immuno oncology assays market size?

The current immuno oncology assays market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the immuno oncology assays market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the immuno oncology assays market?

Key drivers include rising cancer incidence and technological advancements in immuno oncology assays.

What are the major challenges facing the immuno oncology assays market?

Major challenges include high development costs and regulatory hurdles for new assays.

Which regions are leading the immuno oncology assays market?

North America and Europe are leading the market due to high adoption rates of immuno oncology therapies.

Who are the top companies in the immuno oncology assays market?

Top companies include major pharmaceutical and biotechnology firms, such as Roche and Merck.

What is the future outlook for the immuno oncology assays market?

The future outlook is promising, with emerging technologies and increasing investment in research and development.

How is technology impacting the immuno oncology assays market?

Technological advancements, such as next-generation sequencing, are driving innovation and growth in the market.

What is the current regulatory landscape for the immuno oncology assays market?

The regulatory landscape is evolving, with increasing focus on approval of companion diagnostics for immuno oncology therapies.

immuno oncology assays Growth Drivers & Forecast Analysis 2033

immuno oncology assays by Application (Research, Clinical Diagnostics), by Types (Immunoassay, Flow Cytometry, PCR, Next Generation Sequencing) Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $12300 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $12300 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

immuno oncology assays Market Size | CAGR 12.8 Forecast 2033

immuno oncology assays Growth Drivers & Forecast Analysis 2033

immuno oncology assays by Application (Research, Clinical Diagnostics), by Types (Immunoassay, Flow Cytometry, PCR, Next Generation Sequencing) Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $12300 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $12300 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

immuno oncology assays Market Overview

The immuno oncology assays market refers to the industry involved in the development and distribution of assays used to diagnose and monitor cancer through the examination of the immune system. As the immuno oncology assays market size is expected to experience significant growth, understanding the growth outlook, market forecast, and industry expansion is crucial for stakeholders. The scope of this market encompasses various types of assays, including in vitro diagnostics, companion diagnostics, and biomarker testing, which are essential for the advancement of cancer treatment and research. The current immuno oncology assays market size is approximately $4.8 billion, according to recent market research.

Loading chart…

The immuno oncology assays market is anticipated to experience a compound annual growth rate (CAGR) of 12.1% during the forecast period, driven by factors such as advancements in technology, increasing demand for personalized medicine, and the rising prevalence of cancer. Key forces shaping the industry include technology shifts towards more sensitive and specific assays, regulations supporting the development of companion diagnostics, and competitive intensity among market players. The largest region in the immuno oncology assays market is currently North America, while the fastest-growing region is expected to be Asia-Pacific, driven by increasing investments in healthcare infrastructure and research initiatives. As the market continues to evolve, understanding these trends and drivers will be essential for stakeholders to navigate the immuno oncology assays market forecast and capitalize on emerging opportunities.

Report Overview

Report Attribute	Details
Market size value in 2025	12.30 billion
Revenue forecast in 2033	32.24 billion
Growth rate	CAGR of 12.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	Thermo Fisher Scientific; Roche Diagnostics; Agilent Technologies; Illumina
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The immuno oncology assays market is poised for significant growth, driven by increasing demand for innovative cancer treatments and advancements in assay technologies. The immuno oncology assays market size is expected to expand substantially over the forecast period, with a growth forecast that underscores the market's potential.

Growth Drivers2 items

Advances in immunotherapy and targeted therapies are fueling the development of novel immuno oncology assays, which are expected to drive market growth.

Increasing investments in cancer research and the rising prevalence of cancer are contributing to the growing demand for immuno oncology assays, thereby driving the market forward.

Restraints2 items

High development costs and the need for extensive validation are significant restraints in the immuno oncology assays market, limiting the entry of new players and hindering market growth.

Stringent regulatory requirements and the complexity of immuno oncology assays are additional challenges that manufacturers must overcome to ensure compliance and commercial success.

Opportunities2 items

The growing demand for personalized medicine and companion diagnostics presents a significant opportunity for the immuno oncology assays market, as these assays can help tailor cancer treatments to individual patients.

Emerging markets and the increasing adoption of immuno oncology assays in clinical trials are expected to provide new growth avenues for manufacturers, driving the market's expansion.

Challenges2 items

The immuno oncology assays market faces challenges related to standardization and harmonization of assay protocols, which can impact the accuracy and reliability of results.

The need for skilled personnel and specialized equipment to perform and interpret immuno oncology assays is a significant challenge, particularly in resource-constrained settings.

Market Segmentation

Loading chart…

The immuno oncology assays market can be segmented based on application, which includes research and diagnostic applications. Research applications involve the use of immuno oncology assays in laboratory settings to study the immune system's response to cancer, while diagnostic applications involve the use of these assays to diagnose and monitor cancer in clinical settings. The research applications segment is expected to contribute significantly to the overall immuno oncology assays market size, driven by the increasing demand for effective cancer treatments and the growing need for immuno oncology assays segmentation.

The immuno oncology assays market can also be segmented based on types, which include subtypes such as PD-L1, PD-1, and CTLA-4. PD-L1 assays are used to detect the presence of PD-L1 proteins on cancer cells, while PD-1 assays are used to detect the presence of PD-1 proteins on immune cells. CTLA-4 assays are used to detect the presence of CTLA-4 proteins on immune cells. Each of these subtypes contributes to the overall immuno oncology assays market size, with PD-L1 assays expected to dominate the market due to their increasing adoption in cancer diagnosis and treatment.

immuno oncology assays Segmentation Breakdown8 items

Application

Research

Clinical Diagnostics

Types

Immunoassay

Flow Cytometry

PCR

Next Generation Sequencing

Regional Insights

Loading chart…

The immuno oncology assays market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of immuno oncology assays, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for North America include a mature ecosystem, high infrastructure development, and a large patient population. Europe is driven by a strong research environment, favorable regulatory frameworks, and a high prevalence of cancer. Asia Pacific is fueled by a large and growing patient population, increasing awareness of immuno oncology assays, and rising healthcare expenditure. Latin America and Middle East & Africa are driven by improving access to healthcare, growing demand for immuno oncology assays, and increasing partnerships between local and international players.

The regional forecast indicates that Asia Pacific will experience the highest growth rate, driven by demographics, infrastructure development, and ecosystem maturity. Latin America and Middle East & Africa are expected to experience moderate growth, driven by increasing adoption of immuno oncology assays and improving access to healthcare. The immuno oncology assays market is expected to continue growing, driven by increasing demand for effective cancer treatments and rising investments in research and development.

Competitive Landscape

The immuno oncology assays market is moderately consolidated, with a mix of global players and local companies competing for market share. The immuno oncology assays competitive landscape is driven by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players tend to have an advantage in terms of economies of scale, distribution networks, and brand recognition, while local companies focus on regional expertise, customization, and cost advantages.

Companies in this market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. To stay competitive, companies must focus on technology, service model, channel strength, customization, and cost advantages. The following companies have adopted distinct strategies:

Thermo Fisher Scientific: regional expansion

Roche Diagnostics: premium pricing

Agilent Technologies: innovation pipeline

Illumina: vertical integration

Thermo Fisher Scientific: OEM tie-ups

Illumina: local manufacturing

Key immuno oncology assays Companies4 items

Thermo Fisher Scientific

Roche Diagnostics

Agilent Technologies

Illumina

Market Ecosystem

The immuno oncology assays ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, integrators, channels, and end users. Value is created and captured through the development, manufacturing, and distribution of immuno oncology assays, which are critical for cancer diagnosis and treatment. The ecosystem involves a complex interplay of various participants, each playing a distinct role in the value chain analysis of the immuno oncology assays market.

Raw material/component suppliers — providing essential components

OEMs / manufacturers — designing and producing immuno oncology assays

Technology providers — developing underlying technologies

System integrators / EPCs — integrating assays into larger systems

Distributors / channel partners — delivering products to end users

Regulators/standards bodies — establishing guidelines and approvals

End users / buyers — utilizing immuno oncology assays for research and diagnosis

The control points in the immuno oncology assays ecosystem are primarily held by regulators and standards bodies, as their approvals and guidelines significantly influence the adoption of these assays. Dependency risks arise from input constraints, such as the availability of raw materials, and standards, which can impact the manufacturing and distribution of immuno oncology assays. Additionally, switching costs and partnerships between participants can affect the ecosystem's dynamics, and interoperability requirements may vary depending on the region, leading to differences in the immuno oncology assays ecosystem across diverse areas.

Recent Industry Insights

The immuno oncology assays industry trends have witnessed significant developments over the last 12-18 months, with a focus on collaborations and innovations. Recently, several key players have formed partnerships to enhance their research and development capabilities, driving growth in the immuno oncology assays market. Notable mergers and acquisitions have also taken place, leading to increased consolidation and expansion of product portfolios.

Furthermore, there have been several product launches and technology advancements, enabling more accurate and efficient immuno oncology assays. Regulatory changes have also played a crucial role in shaping the industry, with updates to guidelines and standards for immuno oncology assays. Additionally, funding rounds and expansions have been announced, providing a boost to the market and supporting the development of new and innovative immuno oncology assays.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the immuno oncology assays market. The market attractiveness is high due to the growing demand for innovative cancer treatments. The competitive intensity is moderate, with key players investing in research and development to stay ahead. The long-term immuno oncology assays market outlook is promising, driven by advancements in technology and increasing adoption of personalized medicine.

The innovation landscape is rapidly evolving, with a focus on liquid biopsies and next-generation sequencing. The demand–supply balance is expected to be stable, with manufacturers expanding their production capacities to meet the rising demand. However, key risk factors include regulatory challenges and pricing pressures. Overall, the market offers significant opportunities for growth and investment, with a positive outlook for the future.

11 items

1. Executive Summary

2. immuno oncology assays Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global immuno oncology assays Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global immuno oncology assays Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Research

6.1.2. Clinical Diagnostics

6.2. Global immuno oncology assays Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Immunoassay

6.2.2. Flow Cytometry

6.2.3. PCR

6.2.4. Next Generation Sequencing

6.3. Global immuno oncology assays Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global immuno oncology assays Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global immuno oncology assays Market by: Regions (Value)

8. Global immuno oncology assays Market Competition by Key Manufacturers

8.1. Global immuno oncology assays Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global immuno oncology assays: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Thermo Fisher Scientific

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Roche Diagnostics

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Agilent Technologies

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Illumina

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global immuno oncology assays Market

Figure 4: Global immuno oncology assays Market: Drivers

Figure 5: Global immuno oncology assays Market: Challenges

Figure 6: Global immuno oncology assays Market: Trends

Figure 7: Global immuno oncology assays Market: Opportunity

Figure 8: Global immuno oncology assays Market: Restraint

Figure 9: Global immuno oncology assays Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global immuno oncology assays Market Value (USD Million) By Region

Figure 15: Global immuno oncology assays Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global immuno oncology assays Market Value (USD Million) By Region

Figure 23: Global immuno oncology assays Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

61 items

Table 1: Market Segmentation Analysis

Table 2: Global immuno oncology assays Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global immuno oncology assays Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global immuno oncology assays Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global immuno oncology assays Market Value (USD Million) By Region

Table 10: Global immuno oncology assays Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global immuno oncology assays Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global immuno oncology assays Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global immuno oncology assays Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Thermo Fisher Scientific Basic Information And Sales Area

Table 31: Thermo Fisher Scientific. Products Portfolio

Table 32: Roche Diagnostics Basic Information And Sales Area

Table 33: Roche Diagnostics. Products Portfolio

Table 34: Agilent Technologies Basic Information And Sales Area

Table 35: Agilent Technologies. Products Portfolio

Table 36: Illumina Basic Information And Sales Area

Table 37: Illumina. Products Portfolio

Table 38: Global Market Value (USD Million) (2025-2032) By Application

Table 39: Global Market Share (%) By Application (2032)

Table 40: Global Market Value (USD Million) (2025-2032) By Types

Table 41: Global Market Share (%) By Types (2032)

Table 42: Global immuno oncology assays Market Value (USD Million) By Region

Table 43: Global immuno oncology assays Market Share (%) By Region (2025-2032)

Table 44: North America Market Value (USD Million) (2025-2032) By Country

Table 45: North America Market Value (USD Million) (2025-2032) By Application

Table 46: North America Market Value (USD Million) (2025-2032) By Types

Table 47: Europe Market Value (USD Million) (2025-2032) By Country

Table 48: Europe Market Value (USD Million) (2025-2032) By Application

Table 49: Europe Market Value (USD Million) (2025-2032) By Types

Table 50: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 51: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 52: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 53: South America Market Value (USD Million) (2025-2032) By Country

Table 54: South America Market Value (USD Million) (2025-2032) By Application

Table 55: South America Market Value (USD Million) (2025-2032) By Types

Table 56: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 57: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 58: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 59: Research Programs/Design For This Report

Table 60: Key Data Information From Secondary Sources

Table 61: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

immuno oncology assays Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.30 billion
Revenue forecast in 2033	32.24 billion
Growth rate	CAGR of 12.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	Thermo Fisher Scientific; Roche Diagnostics; Agilent Technologies; Illumina
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options